Project description
Glioblastoma (GBM) is the most common type of brain tumour in adults, representing 15.4% of all primary brain tumours. GBM has a poor overall survival rate of less than 10% after 5 years and this, and the lack of advancement in treatment options in the last decade, make the discovery and development of novel therapies a priority. By combining the expertise available within GW4Cancer in basic and translational GBM research, we are in a unique position to discover and validate novel drug targets for GBM, which could benefit brain tumour patients. The role for altered metabolism in cancer cells growth was first proposed by Otto Warburg over 70 years ago. Recent discoveries have firmly established that altered metabolism fuels GBM growth and aggressiveness. Importantly, we have now found that the expression of a novel E3 ubiquitin ligase involved in protein degradation is upregulated in GBM; that this enzyme is important for cell growth and proliferation; and using proteomics we have shown that it interacts with and potentially regulates metabolic proteins. We therefore propose that upregulation of this E3 ubiquitin ligase could lead to the rewiring of GBM's metabolic state into one permissive for malignant transformation.
The student will work as part of a multidisciplinary team of scientists with strong expertise in both basic and translational cancer research. The work will mostly be carried out in the Licchesi lab (https://julienlicchesi.wordpress.com/) which made the original observations and which has expertise in studying protein ubiquitination using cellular and biochemical techniques. The Smalley and Siebzehnrubl labs (Cardiff) will provide access, expert knowledge and training on the use of in vivo models to study GBM tumourigenesis. Dr Kathreena Kurian, expert neuropathologist for brain tumour research (Bristol) will provide access to fully consented specimen with clinical follow up as well as training in translational GBM research. The project also benefits from on-going collaboration with chemical biologists (University of Dundee) and proteomics experts (University of Oxford).
Eligibility
Applicants for a studentship must have obtained, or be about to obtain, a First or Upper Second-Class UK Honours degree in Biochemistry or Molecular & Cellular Biology. Full awards (fees plus maintenance stipend) are open to UK Nationals and EU students (primarily those who can satisfy the RCUK UK residency requirements but a limited number of studentships are available for those who do not meet the requirement of being resident in the UK for three years).
Previous laboratory experience including an undergraduate placement or a Master's Degree in Cancer Biology is essential. We are looking for a highly motivated student who is passionate about research and with an excellent work ethic. Interested applicants should contact Dr Licchesi to discuss suitability for the project prior to submitting a formal application.
Funding notes
Studentships consists of full UK/EU tuition fees, as well as a Doctoral Stipend matching the UK Research Council National Minimum (£14,553 p.a. for 2017/18, updated each year). This is to cover costs such as research consumables, training, conferences and travel. Additional funds are also available for high-cost training/research. Each studentship provides funding for 3.5 years, which may be extended if additional specialist training is integral to the project. Deadline Applications will apply via centralised online application form, between 25 th September and 9am 24th November 2017 (http://www.gw4biomed.ac.uk/projects-2/for-students/). https://www.findaphd.com/search/ProjectDetails.aspx?PJID=88792&LID=69
